Generation of Tet-HGF-G361 cell line
The Tet-HGF-G361 cell line was generated using the ViraPower™ HiPerform™ T-REx™ Gateway ® Expression System from Life Technologies. G361 parental cells were transduced with lentivirus that constitutively express high levels of the Tet repressor under control of the cytomegalovirus (CMV) promoter. Following selection with 500 μg/mL neomycin, cells were transduced with lentivirus expressing human HGF under control of the Tetregulated, hybrid CMV/TO promoter. Tet-HGF-G361 cells were selected with 5 μg/mL blasticidin.
Flow cytometry
Cell surface expression of MET was measured with a mouse anti-human MET PE-conjugated antibody (R&D Systems). A mouse Immunoglobulin G PEconjugated antibody (SouthernBiotech) was used as an isotype control. Antibodies were diluted (250 ng/mL) for staining reactions with cultured cells (1 × 10 6 cells/mL) in fluorescence-activated cell sorting buffer (phosphatebuffered saline [PBS] + 1% fetal calf serum + 0.01% NaN 3 ). Samples were run on an LSR-II flow cytometer (BD Biosciences), counting 20,000 events/treatment condition. Analysis was performed using FCS Express Research v4 software (De Novo Software).
Immunoblot analysis
Samples were prepared at normalized concentrations in NuPAGE ® LDS Sample Buffer per manufacturer protocol, electrophoresed on 10% Bis-Tris NuPAGE ® gels (Life Technologies), transferred to 0.45 μm polyvinylidene fluoride membranes, and blocked in 5% milk/trisbuffered saline with Tween 20 (TBST). Membranes were incubated with total or phospho-specific antibodies at 1:1000 dilutions (beta-actin at 1:5000) in either 5% milk/TBST (total protein) or 5% bovine serum albumin/ TBST (phosphorylated protein) overnight at 4°C. Proteins were detected with horseradish peroxidase-conjugated antibodies, SuperSignal ® West Pico or Dura Extended Duration Substrate (Thermo Fisher Scientific), and the ChemiDoc™ Imaging System (Bio-Rad).
Electro-chemiluminescence immuno assay
Standard curves were performed using control cell lysates containing high levels of target protein (11-step, four-fold dilution series). Unknown samples were profiled at 25 μg/well. Electrochemiluminescent signals for unknown samples were confirmed to be in the linear range of the standard curve; relative concentrations of unknown samples were calculated by MSD workbench software. All samples were run in duplicate. Figure 3B . (C) As described in S3A but with PD0325901 (1 µM) substituted for vemurafenib.
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